As anyone with experience of non-small-cell lung cancer will tell you, one drug does not fit all. When we first started working with AstraZeneca in this area, 15% of patients were receiving the wrong treatment. That’s a heck of a lot.
EGFR testing can help physicians make much better informed decisions about the treatment a patient needs. But many thought testing took too long. Our goals were simple: increase patient testing, reduce the wait time for results, and standardise the procedure to make everything run more smoothly.